ClinicalTrials.gg

Program

GS-5319

A development code.

Its studies are led by Gilead Sciences.

Furthest: phase 1, since Aug 13, 20251 company-led study, 1 open or runningNext primary completion: May 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences11 open or runningphase 1since Aug 13, 2025Aug 13, 2025May 2028phase 1 · NCT07128303

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 13, 2025First study: phase 1 study in Advanced Solid TumorFirst studyNCT07128303 · 476 planned · United States, South Korea, Spain

Ahead

  1. May 2028Primary completion: phase 1 study in Advanced Solid TumorNCT07128303

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07128303Advanced Solid Tumor · United States, South Korea, Spain1RecruitingMay 2028476

How it is read

Names in the registry

  • “GS-5319”, 1 entry

Codes read as this program: GS5319.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.